OBJECTIVES: Pulmonary lobectomy is the most commonly performed surgery for lung cancer and remains the gold standard operative treatment. The reported surgical mortality from this procedure rarely differentiates between in-hospital mortality (IHM) and early postdischarge mortality (PDM). We aimed to examine the IHM and 90-day PDM over time and identify outcome predictors including patient characteristics, comorbidity and system-level factors.
INTRODUCTION
Lung cancer carries a significant burden of mortality on healthcare systems worldwide and is regarded as the leading cause of cancer death in both males and females. In Canada, 25 500 patients were estimated to have been diagnosed with lung cancer in 2013 and 20 200 will die from this disease [1] . Although lung resection surgery allows for the best chance of long-term survival in patients with early-stage non-small-cell lung cancer (NSCLC), only 20-25% of patients underwent a lobar (lobectomy or pneumonectomy) resection [2] . Evidence-based guidelines published by the National Comprehensive Cancer Network (USA) and the European Society for Medical Oncology [3, 4] recommend radical anatomical resections, given that they are associated with superior 5-year survival rates and lower rates of local occurrence than lesser resections despite a longer length of stay (LOS) and a higher rate of complications [5] [6] [7] [8] .
A central theme in outcome evaluation is the consideration of mortality. Mortality can be defined in multiple ways depending on the time point and duration under study, resulting in a need for great care when evaluating the literature to avoid erroneously comparing dissimilar studies [9] [10] [11] . Postoperative mortality is often used to evaluate quality improvement initiatives, such as the resultant impact on patient outcomes of the consolidation of lung cancer surgical services into large volume centres [9] . Postoperative mortality can be reported as IHM, 30-day mortality from the date of surgery, 30-day mortality from the date of discharge as well as 90-day analogues, and other traditional longterm metrics. Thirty-day and IHM are most commonly reported, but can be limited as they can be obscured by inter-facility transfers of critically ill patients and by hospital discharge to palliative care at home, respectively. This results in an under-representation of the actual incidence of post-surgical mortality [10] , a fact that was confirmed in the paper by Rodriguez et al., where in-hospital (IHM) and 30-day mortality were reported to represent only half the all-cause post-surgical mortality, demonstrating a need for longer-term data collection [12] . Ninety-day mortality rates are less widely adopted, but show the potential to be a more complete measure of surgical outcome. A lengthened postoperative mortality surveillance period could potentially be of utmost importance in light of recent trends towards a shorter length of hospital stay, increasing numbers of post-discharge deaths and a higher incidence of postoperative complications [11] . For this reason, 90-day post-discharge mortality (PDM) has the potential to become an important outcome indicator although it has been largely overlooked to date.
As thoracic surgery programmes move to develop quality improvement initiatives, the need to identify predictors of death after discharge becomes increasingly important to inform the planning of new initiatives. If predisposing factors are accurately identified, tailored innovations, such as targeted smoking cessation campaigns for example, can be directed towards specific groups of patients to decrease surgical mortality after discharge [10] .
Despite the improvements in surgical and perioperative care, there is still a significant amount of undocumented or ill-defined mortality after lobectomy for NSCLCs within the 90-day postdischarge period [13, 14] .
The objectives of this study are to evaluate IHM and 90-day PDM after lobectomy for NSCLC malignancies using a large-scale population-based data set, and to investigate the potential key predictive factors that may explain this post-lobectomy mortality.
MATERIALS AND METHODS
This study is a retrospective analysis of prospectively collected population-based database. Data were requested from the cd-link program operated by the Institute for Clinical Evaluative Sciences in Ontario, Canada. This data set was assembled from the Canadian Institutes for Health Information (CIHI) in-patient Discharge Abstract Database and out-patient National Ambulatory Care Reporting Service database, which are populated by trained hospital-based data abstractors and submitted to a central data repository. In addition to the Ontario selection of the CIHI database, this data set also included data from Ontario Health Insurance Plan claims and the Ontario Cancer Registry. All data sets feature obligatory data submission of all patient contacts relating to their diagnosis and cancer treatment. This study was approved by the St Joseph's Healthcare Hamilton Research Ethics Board.
The data set includes all patients who underwent thoracotomy or thoracoscopic lobectomy for primary NSCLC from the 2004/ 2005 to 2011/2012 fiscal years (Canadian Classification of Health Interventions procedure code 1.GR.87). The diagnosis was defined by code C34.XX, neoplasm located within the lung, as described by the Canadian adaptation of the International Classification of Diseases 10th revision (ICD-10-CA). Patient-reported tumour histology was reviewed to ensure that only NSCLC cases were included, with adenocarcinoma not otherwise specified, adenocarcinoma mixed subtypes, squamous cell carcinoma not otherwise specified, bronchioalveolar carcinoma and undefined non-small-cell carcinoma reported in analyses.
A number of exclusions were made to increase the generalizability and clarity of the data set. Patients who had previous malignancies were excluded to minimize the potential confounding effect of cancer recurrence on outcomes. Patients who were reported with synchronous tumours and sleeve lobectomy were also excluded due to the heterogeneity of treatment outcomes. Patients with a prolonged LOS, defined as more than 30 days from the day of surgery, were excluded from analysis. The study team felt that these patients [157/5546, or 2.8% of the sample (95% confidence interval (CI): 2.4-3.3%] likely represent those who had an exceptional postoperative experience and as such are no longer comparable with patients with an average LOS.
The multivariate analysis data set included de-identified information of patient demographics, socioeconomic classification, year of surgery, use of staging mediastinoscopy or positron emission tomography (PET), use of minimally invasive surgical approach, operative laterality, length of hospital stay, calculated Charlson Comorbidity Index with individual comorbidity component variables, tumour histology, IHM status and mortality status within 90 days of hospital discharge. The Charlson Comorbidity Index utilizes a priori defined categories to rate an individual's relative morbidity level outside of the current malignancy under treatment. Surgical details such as whether they received an epidural or venous thromboembolism prophylaxis and patient performance status have not been collected by the data abstractors, and as such are not available in this data set. Pathological staging was not collected reliably in this data set during the interval under study.
Descriptive statistics were used to describe patient characteristics. Categorical variables were reported as frequencies and relative frequencies, and continuous variables as means with standard deviations or median with range whenever appropriate. Univariable analysis was performed using the χ 2 or Fisher's exact test for categorical variables and independent samples t-test or the MannWhitney U-test for continuous variables. Potential predictors of IHM were identified through stepwise logistical regression and reported as odds ratios (ORs) with 95% CIs with the corresponding P-value. The P-value for the Hosmer-Lemeshow test as an indicator of the model goodness of fit was also reported. Patients who died in hospital were excluded from subsequent PDM analyses. PDM was examined using Cox proportional hazards modelling with hazard ratios (HRs) used to describe potential predictors of mortality along with 95% CIs and P-values. The Kaplan-Meier curve was plotted for PDM survival data. All tests were two-sided and an alpha 0.05 was utilized for statistical significance. Analysis was completed using SPSS version 22.0 (www.IBM.com) and Minitab version 16.0 (www.minitab.com) software.
RESULTS
Of 5389 patients who underwent lobectomy for NSCLC, 51% were female (n = 2746) and the median LOS was 6 (1-30) days. Histological subtypes included 37.6% adenocarcinoma not otherwise specified (39.6% in patients who died), 24.0% squamous cell carcinoma not otherwise specified (30.7% in deceased patients) and 21.8% other subtypes (17.9% in patients who died). There was no significant difference in patient income quintile (P = 0.10) and Index Year of surgery (P = 0.14) between patients who survived beyond 90 days and those who died.
Seventy-three (1.4%; 1. at 30 days, 98.8% (98.6-99.1%) at 60 days and 98.1% (97.7-98.4%) at 90 days post-discharge. Table 2 describes the patient characteristics of the 5316 remaining patients who were discharged from hospital, which defines the total post-discharge cohort. The univariable comparison (Table 1) showed that age, gender, LOS and mean Charlson comorbidity index were different between survivors and those who died within 90 days. Comorbidities of patients in the PDM cohort are described in Table 3 . Surprisingly, the rate of primary cancer was lower in those who died than those who survived.
The stepwise Cox proportional hazard model for PDM is reported in Table 4 
DISCUSSION
Survival is the ultimate goal of surgical treatment for lung cancer. As clinicians, we strive to minimize perioperative complications but, in particular, we endeavour to avoid mortality. This key outcome is described using various time points and often without any sort of consideration of the postoperative post-discharge period. This ambiguity and missing information means that any conclusions drawn from the literature are limited as a result of not knowing the postdischarge status of the patients. As this and other studies have shown, the post-discharge period of time actually results in more postoperative mortality than the in-hospital time frame [9, 10] . As such, quality improvement initiatives should examine this important outcome and strive to minimize its occurrence. When the specific variables outlined in the multivariate analysis are examined, it becomes apparent that IHM is driven mostly by patient age and comorbidities. Factors such as ischaemic heart disease, CHF and MI all significantly increase the perioperative risk. This is intuitive to surgeons, who would recognize that these are significant comorbidities. Interestingly, patients who have had a second primary malignancy, in the lung or in another site, within 5 years of the lobectomy-resected lung tumour, appear to have a lower risk of IHM. While this comorbidity certainly would be a marker of existing patient risk factors, this apparent protective effect may represent additional patient contact in hospital with health-care staff or another unknown in-hospital effect.
One of the strengths of this analysis is the quantification of preexisting patient risk factors, but the interpretation of these data has to be tempered by an awareness of the event frequency.
Hemiplegia, for example, is a very high-risk illness, but occurs only in 9 patients in this data set. Other variables such as whether a PET scan was performed and year of the surgical procedure also need to be interpreted cautiously. PET scan during this study period was not universally available and, as such, it may be a marker for more experienced centres rather than anything relating to the within-patient factors. This study shows a protective effect of surgical year that is consistent with the general decrease seen in perioperative mortality for surgical procedures. This likely relates to multifactorial system improvements in perioperative care such as the regionalization of cancer surgical services in high-volume centres or complication benchmarking initiatives [15] [16] [17] [18] .
The 90-day post-discharge time period features predictors of mortality that share some similarity with those that indicate a risk of IHM, but there are some important differences. As with IHM, patient factors are vitally important. Age, male gender and a history of metastatic cancer are significant, but cardiac and respiratory variables are not. This suggests less of an effect of standard comorbidities and a greater effect of non-modifiable variables such as age and gender. The effect of duration of hospital stay on PDM is particularly disconcerting. Not surprisingly, the longer the LOS, the higher is the post-discharge risk. This all adds up to factors predictive of a fragile patient being at an elevated risk once discharged, and this patient must be managed carefully in followup to minimize the risk of mortality in this high-risk period.
All analysis of administrative databases needs to be interpreted with knowledge of their inherent strengths and weaknesses. The data collection process is standardized and very comprehensive in a single-payer system like that of Canada. There are regimented procedural processes to ensure a high quality of data, including annual re-abstraction of specific variables, which has found the data collection process to be reliable and reproducible [19] . This provides a very comprehensive dataset where patients are not lost to follow-up and their postoperative events are captured reliably. The collection and subsequent recording of those comorbidities is completed by trained data abstractors, yet their level of knowledge is not similar to clinicians who work with specific defined criteria. The fact that the data utilized for this analysis was captured from administrative databases and linked together using unique patient identifiers offers a distinct advantage in that there is an expected level of completeness and validity to the data set. The disadvantage to this approach is that certain variables known by the thoracic surgery community to influence patient mortality such as patient preoperative performance status or other comorbidities not included in the Charlson Comorbidity Index are not entered and as such are not available for consideration in the models. Patient stage is collected but not reliable at the present time, and so it was not included in multivariate models, although stage is well known to influence patient outcomes. Additionally, systemic extrinsic factors such as access to PET scans are unknown and, thus, the results need to be interpreted with caution. Despite these limitations, the notably large sample size of this study likely contributes to a more powerful analysis and more reliable and precise estimates of death rates and their potential predictors. This study demonstrated that patients undergoing lobectomy for NSCLC experience a greater risk of death after discharge from hospital compared with when they are admitted as in-patients. While the variables identified in this analysis do not represent the definitive list of predictors of mortality, they represent possibilities that surgeons have a responsibility to consider when aiming to improve the delivery of quality care. This underscores the need for surgeons to explore this post-discharge time frame in a prospectively collected study design to elucidate reasons for this elevated mortality and seek novel approaches to improve this important outcome. Whether this includes extended venous thromboembolism prophylaxis, targeted arrhythmia management or better care of the elderly population, to name a few potential interventions, we need to devise thoughtful approaches to care for these patients at a higher risk of mortality during the postoperative follow-up period. discharge the patients. There are things like pulmonary embolisms, fatal arrhythmias, that are coming to bear, or the patients aren't accessing care, and we need to support them. We started local initiatives where our patients now can call a nurse 24 h a day out to 90 days from their hospitalization, someone they can call right away. It keeps them out of the emergency department, it allows us to reach out to them, but I think until we know what we are talking about, we can't improve it.
Certainly there is the POISE-2 study and other studies that have suggested that a bump in your troponin postoperatively puts you at increased risk; they have tried interventions like alpha blockers, beta blockers, that have not shown any improvement. But we are proposing studies like continued Holter monitors for patients (which they can now wear out to 90 days), and DVT prophylaxis. One of my partners is doing a study on that, and I think that's where we can make improvements in care by looking closely and systematically, and logically assessing how we can continue to improve.
Dr D'Amico: Lastly, it didn't look like that curve was plateauing at 90 days. Dr Finley: It starts to flatten out. Their excess mortality seems to fall out. Dr H. Eid (Dubai, United Arab Emirates): I just want to ask you, where is the benefit? We know that operative mortality occurs within 30 days from surgery. Any patient can die at any time from any disease. So what is the relationship to the resection if the patient dies after three months or six months if you don't have statistics to show why these patients died?
Dr Finley: In Canada, the rate of death for a person between 65 and 74 is 1.5% per year. So until your mortality falls to less than 0.1% per month (for analysis on a per-month basis), then I think that we have excess mortality, and these people are dying off at a rate of about 0.8% per month. So until their mortality falls to the same rate as their peers, we are responsible; our intervention is causing them increased mortality and we need to bear that responsibility. The 30-day mortality cut-off is an arbitrary one, as is 90 days. I think that we should be responsible until they reach the same level as their peers.
Dr J. Schirren (Wiesbaden, Germany): We learned from the States that the patient has to leave the hospital. We know that you send the patient away after three or four days. Now the question is, the follow-up: they do not go home; they are in a hotel or somewhere approximating a hotel. Are the medical staff comparable with the staff in the hospital?
Dr Finley: In Canada, we don't get to sneak them out to hotels, but you are right: we try to get our patients home very quickly. Akin to McKenna, we are aiming for postop day two, day three VATS lobectomy, discharge. But this new programme where we follow our patients I think sits well with me, because I feel very responsible for people. I had a pneumonectomy patient die at home 12 days after surgery for no apparent reason; his wife woke up with him, and I feel horrible for that. But our responsibility is there and we need to provide the care we do in a cost effective manner, and we need to deliver the care in-hospital that needs to be delivered in-hospital, but I think that we need to feel ownership of those people forever, and any intervention and improvement that we can make as physicians we need to undertake. So I think that the old "surgical wave to them at the door" is gone. We need to sort of bear that cross forever.
Dr Schirren: Then you would also say that the perioperative care of the patient has to be in the hands of the surgeon?
Dr Finley: Yes. Dr Schirren: Of the surgeon who has done the surgery? Dr Finley: Preoperatively and postoperatively.
